Robert Jobe, MD
Interventional Cardiology · Raleigh, NCNPI 1154329670
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $133,045 of the $190,509 with a category attached, or 69.8%. 30 manufacturers reported payments, led by Chiesi USA, Inc. at 48.8% of the total. Reporting peaked in 2023 at $76,346 and has fallen 69.2% since, to $23,509 in 2025. Among interventional cardiology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 211 payments — averaging $902.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$93K
- Shockwave Medical, Inc$70K
- Medtronic$19K
- Boston Scientific$3K
- Ancora Heart, Inc.$2K
- Abiomed$1K
- plus $2K from 24 others
Across 47 payments — averaging $7887.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$138K
- Boston Scientific$116K
- Philips North America LLC$94K
- Abbott$19K
- Boehringer Ingelheim$2K
- Abiomed$90
What the payments were for
- Consulting fees$45,24024%
- Speaking & faculty fees$133,04570%
- Travel & lodging$6,0333%
- Food & beverage$6,0323%
- Education$10%
- Gifts$1590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 20 | $92,936 |
| Shockwave Medical, Inc | 34 | $70,118 |
| Medtronic(2 entities) | 38 | $19,077 |
| Boston Scientific | 19 | $3,247 |
| Ancora Heart, Inc. | 8 | $2,179 |
| Abiomed | 10 | $1,118 |
| Abbott | 31 | $879 |
| Cordis US CORP. | 6 | $183 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $148 |
| Cardiva Medical, Inc. | 2 | $78 |
| AstraZeneca | 5 | $74 |
| Johnson & Johnson | 4 | $64 |
| Teleflex LLC | 2 | $46 |
| Novartis | 3 | $46 |
| Amgen | 3 | $45 |
| Terumo Medical Corporation | 2 | $35 |
| Davol Inc. | 1 | $33 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Angiodynamics, Inc. | 1 | $19 |
| Cook Medical LLC | 1 | $19 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| Sirtex Medical Inc | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Gilead | 1 | $12 |
| W. L. Gore & Associates, Inc. | 1 | $12 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$69,386
- COREVALVE EVOLUT R$15,829
- AccuCinch$2,121
- GENERAL - THERAPIES$2,117
- Micra$1,440
- SYMPLICITY G3$985
- Impella$846
- AVVIGO Guidance System$681
- COROFLOW$190
- Xience Sierra Coronary Stent System$174
- 3F$162
- KENGREAL$130
- GENERAL - STRUCTURAL HEART$125
- Resolute$119
- AMPLATZER TALISMAN$102
How this compares
$190,509 in reported general payments places this provider in the 90th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 231 | $170,069 |
| Repatha SureclickEvolocumab | 82 | $72,331 |
| EntrestoSacubitril/Valsartan | 33 | $38,194 |
| XareltoRivaroxaban | 27 | $26,193 |
| Praluent PenAlirocumab | 17 | $11,524 |
| Ranolazine ErRanolazine | 138 | $10,253 |
| Repatha SyringeEvolocumab | 22 | $9,362 |
| ClopidogrelClopidogrel Bisulfate | 548 | $5,395 |
| Prasugrel Hcl | 114 | $4,962 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 349 | $3,410 |
| Flecainide Acetate | 81 | $2,519 |
| Losartan Potassium | 202 | $2,178 |
| Metoprolol Succinate | 150 | $1,905 |
| Atorvastatin Calcium | 239 | $1,427 |
| Ezetimibe | 55 | $1,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $46 | $38,19433 claims |
| Johnson & JohnsonXarelto | $64 | $26,19327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Raleigh
- Ravish SacharRaleigh$1.6M
- James ZidarRaleigh$57K
- Willis WuRaleigh$56K
- Islam OthmanRaleigh$50K
- Andrew SampsonRaleigh$48K
- Dwijesh PatelRaleigh$40K
- Siva KethaRaleigh$19K
- Mohit PasiRaleigh$16K
- George AdamsGarner$4.1M
- Paul MahoneyGreenville$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.